Handful of biotechs expected to IPO this fall, but many are stuck in ‘holding pattern’ until 2024
A pair of late-stage biotechs submitted IPO plans last week as industry insiders gear up for what could be a handful of post-Labor Day public debut pitches.
To repeat: That’s a handful of IPOs, not an overflowing basket of filings like the days of 2021 that saw at least 100 biotech IPOs. But any sign of biotechs lining up to ring the trading floor bell could give hope to their privately-held fellows. If members of the fall class and the late July cohort are successful in their first few months of trading, then more startups may have the confidence to pursue public markets next year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
